Suppr超能文献

原发性肝癌切除术和挽救性移植的危害和益处。

Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma.

机构信息

Liver and Multiorgan Transplant Unit, University of Bologna, Italy.

出版信息

Am J Transplant. 2010 Mar;10(3):619-27. doi: 10.1111/j.1600-6143.2009.02984.x. Epub 2010 Jan 29.

Abstract

Primary transplantation offers longer life-expectancy in comparison to hepatic resection (HR) for hepatocellular carcinoma (HCC) followed by salvage transplantation; however, livers not used for primary transplantation can be reallocated to the remaining waiting-list patients, thus, the harm caused to resected patients could be balanced, or outweighed, by the benefit obtained from reallocation of livers originating from HCC patients first being resected. A Markov model was developed to investigate this issue based on literature data or estimated from the United Network for Organ Sharing database. Markov model shows that primary transplantation offers longer life-expectancy in comparison to HR and salvage transplantation if 5-year posttransplant survival remains higher than 60%. The balance between the harm for resected patients and the benefit for the remaining waiting list depends on (a) the proportion of HCC candidates, (b) the percentage shifted to HR and (c) the median expected time-to-transplant. Faced with a low proportion of HCC candidates, the harm caused to resected patients was higher than the benefit that could be obtained for the waiting-list population from re-allocation of extra livers. An increased proportion of HCC candidates and/or an increased median time-to-transplant could lead to a benefit for waiting-list patients that outweighs this harm.

摘要

与肝切除(HR)后挽救性移植相比,原发性肝移植可为肝细胞癌(HCC)患者提供更长的预期寿命;然而,未用于原发性移植的肝脏可以重新分配给其余等待名单上的患者,因此,切除患者所受到的伤害可以通过重新分配首先切除的 HCC 患者的肝脏所获得的益处来平衡,甚至超过。基于文献数据或从器官共享联合网络数据库估计,开发了一个马尔可夫模型来研究这个问题。马尔可夫模型表明,如果移植后 5 年生存率仍高于 60%,与 HR 和挽救性移植相比,原发性肝移植可为患者提供更长的预期寿命。切除患者的伤害与剩余等待名单的获益之间的平衡取决于(a)HCC 患者的比例,(b)转移到 HR 的百分比,以及(c)中位预期移植时间。面对低比例的 HCC 患者,切除患者所受到的伤害大于重新分配多余肝脏为等待名单人群带来的获益。增加 HCC 患者的比例和/或中位移植时间的增加可能会使等待名单上的患者获益超过这种伤害。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验